Vaccines for Bacteria from Spirochete Family
Creative Biolabs provides global solution for worldwide customers in the field of vaccine development. We have successfully accomplished many projects in vaccine development services for bacteria from spirochete family. We guarantee the finest results for our customers all over the world.
Spirochete, a family of bacteria, including Treponema pallidum and Borrelia burgdorferi, are long and slender bacteria in humans and other mammals. They are related to many diseases, such as syphilis, Lyme disease as well as relapsing fever, which cause widespread infections in America. They are Gram-negative bacteria and replicate their genome in close association with reorganized intracellular host cell membrane compartments. At present, six genera have been identified in this family, which play important roles in our lives. Currently, there are many groups and institutions aiming at developing effective and safe vaccines targeted on the member of spirochetes family.
Fig.1 Progression of Lyme Disease in Humans Following B. burgdorferi Infection. (Kumar D, et al., 2015)
Treponema pallidum Vaccines
Treponema pallidum is a bacterium which can cause a variety of diseases, such as syphilis, bejel, and yaws. It is one of the most pathogenic bacteria in mammalian and usually spreads by sexual contact and vertical transmission. Its clinical manifestations range from inflammatory responses to other diseases imitation. The patients infected by Treponema pallidum will have a long latent period before showing some signs or symptoms, which can make them more infectious and dangerous. There are many vaccine target proteins of Treponema pallidum being developed, such as 4D, Tp92 (BamA), Tp0155, and endoflagella, which play important roles in the incidence of Treponema pallidum infections.
Borrelia burgdorferi Vaccines
Borrelia burgdorferi, a tick-borne bacterium, belonging to the spirochete family. They are responsible for many cases of Lyme disease in most countries around the world. Lyme disease is normally found in cold regions, but the biogeographical distribution of the disease has changed because of the climate change. There are a number of clinical features of disease, like erythema migrans, fever, chills, and muscle pain. Research suggest that it could tend to develop arthritis in untreated patients. However, no vaccine has been proved to be safe and widely used in Lyme disease therapy. Most vaccines are still on the process of laboratory phase or clinical trial. Recent studies demonstrate that an OspA vaccine has shown the efficacy in B. burgdorferi prevention in mice model, which could be a promising candidate vaccine for Lyme disease.
Our Services for Vaccines for Bacteria from Spirochete Family
Our platform provides a seamless, high-quality, single-source value chain from discovery to commercialization in spirochete family project. As a research-driven and customer-focus company, we are dedicated to helping our worldwide customers shorten the discovery and development time and lower the cost of vaccine development process.
- Mature vaccine development system
- Experienced design and solutions to vaccine development
- Efficient and time-saving discovery system
Creative Biolabs is a professional vaccine development expert with extensive experience in the vaccine development services for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.
Reference
- Kumar D, et al. (2015). “Intravital Imaging of Vascular Transmigration by the Lyme Spirochete: Requirement for the Integrin Binding Residues of the B. burgdorferi P66 Protein.” PLoS Pathog. 11(12), e1005333.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
